New features in MEK retinopathy
Abstract Background The use of molecularly targeted therapy is becoming widespread in oncology. These agents cause tumour-specific genetic alterations in signal transduction pathways, hence less generalised toxicity. Dabrafenib, a BRAF inhibitor and Trametinib, a MEK inhibitor are two molecularly ta...
Na minha lista:
| Principais autores: | , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BMC
2018-09-01
|
| 叢編: | BMC Ophthalmology |
| 主題: | |
| 在線閱讀: | http://link.springer.com/article/10.1186/s12886-018-0861-8 |
| 標簽: |
沒有標簽, 成為第一個標記此記錄!
|